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DOI 10.1186/s12936-015-0665-8RESEARCH Open AccessRobust, reproducible, industrialized, standard
membrane feeding assay for assessing the
transmission blocking activity of vaccines and
drugs against Plasmodium falciparum
Tao Li1†, Abraham G Eappen1†, Adam M Richman1, Peter F Billingsley1, Yonas Abebe1, Minglin Li2, Debbie Padilla1,
Isabel Rodriguez-Barraquer3, B Kim Lee Sim1,2 and Stephen L Hoffman1*Abstract
Background: A vaccine that interrupts malaria transmission (VIMT) would be a valuable tool for malaria control
and elimination. One VIMT approach is to identify sexual erythrocytic and mosquito stage antigens of the malaria
parasite that induce immune responses targeted at disrupting parasite development in the mosquito. The standard
Plasmodium falciparum membrane-feeding assay (SMFA) is used to assess transmission-blocking activity (TBA) of
antibodies against candidate immunogens and of drugs targeting the mosquito stages. To develop its P. falciparum
sporozoite (SPZ) products, Sanaria has industrialized the production of P. falciparum-infected Anopheles stephensi
mosquitoes, incorporating quantitative analyses of oocyst and P. falciparum SPZ infections as part of the manufacturing
process.
Methods: These capabilities were exploited to develop a robust, reliable, consistent SMFA that was used to assess
188 serum samples from animals immunized with the candidate vaccine immunogen, Pfs25, targeting P. falciparum
mosquito stages. Seventy-four independent SMFAs were performed. Infection intensity (number of oocysts/mosquito)
and infection prevalence (percentage of mosquitoes infected with oocysts) were compared between mosquitoes fed
cultured gametocytes plus normal human O+ serum (negative control), anti-Pfs25 polyclonal antisera (MRA39 or
MRA38, at a final dilution in the blood meal of 1:54 as positive control), and test sera from animals immunized with
Pfs25 (at a final dilution in the blood meal of 1:9).
Results: SMFA negative controls consistently yielded high infection intensity (mean = 46.1 oocysts/midgut, range
of positives 3.7-135.6) and infection prevalence (mean = 94.2%, range 71.4-100.0) and in positive controls, infection
intensity was reduced by 81.6% (anti-Pfs25 MRA39) and 97.0% (anti-Pfs25 MRA38), and infection prevalence was
reduced by 12.9 and 63.5%, respectively. A range of TBAs was detected among the 188 test samples assayed in
duplicate. Consistent administration of infectious gametocytes to mosquitoes within and between assays was
achieved, and the TBA of anti-Pfs25 control antibodies was highly reproducible.
Conclusions: These results demonstrate a robust capacity to perform the SMFA in a medium-to-high throughput
format, suitable for assessing large numbers of experimental samples of candidate antibodies or drugs.
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Malaria is a prominent cause of morbidity and mortality
in much of the world, with particularly devastating con-
sequences for children and pregnant women in sub-
Saharan Africa [1]. Malaria parasites are transmitted via
the bite of infected female anopheline mosquitoes. While
insecticide-treated nets, anti-malaria drugs, and indoor
residual spraying of insecticides have together contrib-
uted to significant decreases in malaria incidence in
many parts of Africa, the emergence and spread of drug-
resistant parasites and insecticide-resistant mosquitoes
are ever-present risks [2,3] that potentially threaten the
recent gains in malaria control. It is now widely
acknowledged that eliminating malaria from defined
geographic areas will require additional tools [4]. The most
effective vaccine-based strategy for malaria elimination
would target both the pre-erythrocytic stage of the parasite
life cycle to prevent infection, disease, and transmission of
the parasite to mosquitoes, and the sexual erythrocytic and
mosquito stages of the life cycle to prevent transmission,
thus breaking the cycle of malaria transmission [4,5]. To
develop a sexual-mosquito stage vaccine that interrupts
malaria transmission (VIMT), antibodies are induced
against promising target antigens and the resulting antisera
are tested for transmission-blocking activity (TBA) using a
standard membrane-feeding assay (SMFA) [6] in which test
antisera are mixed with Plasmodium gametocytes cultured
in vitro and fed to susceptible mosquitoes through an arti-
ficial membrane. The transmission-blocking activity (TBA)
of test sera is calculated based on comparison of infection
prevalence and intensity with that obtained in mosquitoes
fed gametocytes mixed with control pre-immune serum.
While the SMFA is an essential tool for developing a
sexual and mosquito stage VIMT, it is a labour-intensive,
time consuming, and expensive assay that is subject to
variability both within and between individual assays. To
mass screen antibodies and drugs, a reliable, consistent
and scalable SMFA is needed. To conduct industrial level
SMFAs requires the continuous and reliable production of
mature and highly infectious Plasmodium falciparum
(Pf) gametocytes and healthy malaria-susceptible female
Anopheles mosquitoes, infection of the mosquitoes by
feeding them with gametocytes through an artificial mem-
brane in the presence of negative and positive control
sera, and assessing the mosquito infection levels by count-
ing the number of oocyst stage parasites approximately
one week after feeding.
In order to develop its P. falciparum sporozoite
(SPZ)-based products, Sanaria has established industrial
capabilities for production of Anopheles stephensi mosqui-
toes infected with the NF54 strain of P. falciparum, and
systematic quantitative analysis of oocyst and sporozoite
infections [7]. Exploiting these capabilities, Sanaria de-
veloped a robust, reliable, and consistent SMFA serviceto assess gametocytocidal and transmission blocking
activity of drugs [8]. This service was subsequently scaled
to undertake an industrialized screening of candidate
transmission blocking serum samples for a commercial
client. This paper demonstrates the successful assessment
in duplicate of 188 serum samples for transmission-
blocking (TB) activity in 74 independent SMFAs. The out-
comes of these assays, demonstrating the feasibility of
using the SMFA to reliably assess relatively large numbers
of experimental samples are reported, and demonstrate
that the patterns of infection are reproducible among
assays.
Methods
Parasites
Plasmodium falciparum strain NF54 parasites, from
Sanaria’s working cell bank, were cultured using human
erythrocytes [8,9] in RPMI 1640 medium supplemented
with human O+ serum and hypoxanthine. Gametocyto-
genesis was induced in blood stage parasites by main-
taining the cultures with daily complete growth medium
replacement and without the addition of fresh erythrocytes
for 17–19 days. After 18 ± 1 (mean ± SD) days post
induction, cultures were screened for use in SMFA based
on abundance of mature Stage V gametocytes, exflagella-
tion activity of microgametocytes and macrogametocyte:
microgametocyte ratio.
Mosquitoes
An A. stephensi strain SDA500 [10] colony was main-
tained in an insectary at 27 ± 1°C, 78 ± 5% RH, and a
12:12 light/dark cycle including 0.5 h dawn and dusk in-
tervals. Larvae were fed a diet of Liquifry™ and Tetra-
min™ fish food. Adult mosquitoes were maintained in
30 × 30 × 30 cm cages, with sugar and water available
ad libitum.
Antibodies
Pre-immune sera and sera from placebo-vaccinated animals
were used as negative controls for each SMFA. Positive
control Pfs25 polyclonal antisera were obtained from
MR4: TBV25H/2197 (MRA39), and TBV25H/2198
(MRA38). Both were deposited by Dr D C Kaslow [11].
MRA38 and MRA39 antisera were diluted 1:54 for use in
SMFA. One-hundred and eighty-eight serum samples
from mice immunized with Pfs25-based immunogens
were obtained from Fraunhofer USA Center for Molecular
Biotechnology (FhCMB) [12,13]. All sera were provided as
blinded samples.
Standard membrane feeding assay (SMFA)
Artificial blood meal preparation
Cultured stage V gametocytes were combined with unin-
fected human erythrocytes and serum to a final gametocyte
Figure 1 Intensity of Plasmodium falciparum oocyst infections
in a representative SMFA. The results are shown for one of 74
SMFAs conducted for this study. Each point represents the number
of oocysts per mosquito and the black bar indicates the geometric
mean for each group. Boxes are 95% confidence intervals around
the geometric means. C is non-immune control serum (O+ human
serum). NC is negative control serum (pooled pre-immune mouse
serum). S1 to S6 are serum samples from animals immunized with
Pfs25 immunogens.
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meals were prepared from the same diluted gametocyte
culture. The total volume of each blood meal was 270 μL,
consisting of 150 μL of gametocytes diluted as above, plus
120 μL of serum (human O+ serum alone for negative con-
trol, antiserum against Pfs25 at a 1:54 final dilution in the
blood meal for positive control or test sera of unknown
samples). Use of Pfs25 antisera at 1:54 dilution was based
on studies (data not shown) to identify an antibody
concentration yielding significant reductions in both
intensity and prevalence of oocyst stage (midgut) infections.
For unknown test serum samples, 30 μL of test mouse
serum was combined with 90 μL of human O+ serum and
150 μL of diluted gametocyte culture.
Mosquito feeding and maintenance
Thirty to 35 adult female A. stephensi mosquitoes were
aspirated into a 450 mL cardboard container. The artificial
blood meal maintained at 37°C was pipetted into a
membrane feeding apparatus and presented to the
mosquitoes through an artificial membrane. Each feeding
apparatus was connected in series using rubber tubing
and kept at approximately 37°C by water circulating
through a 38°C water bath. Up to nine containers were
fed simultaneously in one SMFA on individual meals con-
taining negative and positive control sera, and up to six
test mouse sera plus corresponding negative control
mouse serum samples. Mosquitoes were allowed to feed
at ambient temperature until all blood was consumed
from the feeder, typically 20–30 minutes. Immediately
after feeding, the mosquito containers were transferred to
an incubator and thereafter maintained at 26 ± 1°C, 78 ± 5%
RH, with a 12:12 light/dark cycle including 0.5 h dawn
and dusk intervals, and supplied with sugar and water
ad libitum.
Assessment of infection and transmission blocking activity
Six to nine days after feeding, 20–25 mosquitoes per
container were dissected and midguts stained with 0.2%
mercurochrome. Midguts were mounted on glass slides,
and oocysts were counted using a compound micro-
scope. Infection intensity (number of oocysts/mosquito)
and infection prevalence (percentage of mosquitoes in-
fected) were determined. TBA of positive control and
experimental sera was calculated as a percentage reduc-
tion in either oocyst prevalence (TBA-P) or oocyst in-
tensity (TBA-I) compared to the relevant control serum
using the following formulae:
Statistical analysis
The data from 74 different feeding experiments of oo-
cyst counts for all mosquitoes 12 - 27 mosquitoes per
container) in the negative control and Pfs25 (positive
control) groups were analysed in SAS 9.3. Calculation ofthe geometric means of oocysts numbers, percent preva-
lence of oocysts, range of oocyst counts, range of the
positives for oocyst count, and sample size of mosquito
midguts were calculated for both control and Pfs25 sam-
ples. The average of the geometric means was computed
and 95% confidence intervals were calculated. Data in
Figure 1 were plotted using BoxPlotR [14,15].
In order to explore the association between oocyst in-
tensity and prevalence, the methods first described by
Medley et al. [16] were applied. Several functional forms
of the over-dispersion parameter (κ) were assessed and
the best fitting model was chosen based on Akaike’s in-
formation criterion. Independent hyperbolic models
were fitted to the data from the different treatments and
control; 95% confidence bounds were estimated using
1,000 bootstrap samples.
Results
Reproducibility and robustness of SMFA
Seventy-four independent SMFAs were completed as de-
scribed to test in duplicate the TBA of 188 unknown
serum samples. Results of one typical SMFA are shown
(Figure 1). Here, the TBA-I of the anti-Pfs25 MRA39
antibody (positive control) was 89% compared to the
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serum samples ranged from 46 to 100% compared to the
pre-immune pooled serum control.
The data from feeding positive and negative control
sera were used to assess the reproducibility and robust-
ness of the SMFA. For mosquito blood meals containing
the negative control sera, there were robust and consist-
ent oocyst infection intensities and prevalence rates
(Table 1). In the 74 assay negative controls, in which
mosquitoes received gametocytes with normal human
serum, the geometric mean infection intensity was 46.1
oocysts/mosquito (range of positive samples 3.7-135.6),
and mean infection prevalence was 94.2% (range 71.4-
100.0%). Only four negative control feeds had geometric
mean intensities less than ten oocysts/mosquito. A
positive control was included in each SMFA: anti-Pfs25
rabbit antibodies MRA38 or MRA39 mixed with game-
tocytes. The 30 positive controls using MRA38 had a
mean infection (oocyst) intensity of 1.3 (range 0–4.8),
mean TBA-I of 97.0% (range 87.4-100%), and mean
TBA-P of 63.5% (95% Cl = 53.3-73.7) (Table 1). Similarly
for positive controls employing MRA39, the mean TBA-I
was 81.6% (range = 36.5-98.9%) and the mean TBA-P was
12.9% (95% CI = 8.0-17.8) (Table 1). Although there was
variability from assay to assay with respect to infection
intensity in controls, there was little difference in either
TBA-I or TBA-P between assays for the positive control
samples (Table 1).
The consistency of the TBA of the two positive control
antisera in the 74 SMFAs was examined. The TBA-I and
TBA-P were remarkably consistent for the MRA39
antiserum (Figure 2A, C), regardless of the numbers of
oocysts per midgut in the respective control. The TBA-ITable 1 Summary of SMFA control results
Polyclonal anti-sera at
1:54 final dilution
(number of assays)
Infection intensity (number of o
per mosquito)
Negative control Pfs25 antibo
MRA39 (n = 44) Mean ± SD 47.8 ± 32.9 8.4 ± 8.9
95% CI 38.1, 57.5 5.8, 11.1
Range 3.7, 135.6 0.1, 47.0
MRA38 (n = 30) Mean ± SD 43.7 ± 25.8 1.3 ± 1.6
95% CI 34.5, 52.9 0.7, 1.8
Range 7.1, 106.4 0.0, 4.8
Pooled data (n = 74) Mean ± SD 46.1 ± 30.1
95% CI 39.3, 52.5
Range 3.7, 135.6
The positive and negative control data from 74 independent SMFAs are summarize
fed negative control (human O+) serum or positive control anti-Pfs25 antibodies. Tr
prevalence (TBA-P) are calculated. In each SMFA there was one cage of negative co
intensities, data are the arithmetic means ± standard deviation (SD) of the geometr
as well as the 95% confidence intervals (CI) and range. For infection prevalence, da
cage of negative or positive control mosquitoes as wells as the 95% CI and range.was within the 70-100% range in 38 of the 44 assays
(Figure 2A) across all oocyst intensities of the respective
negative controls. However, reduction of prevalence
rates with MRA39 was poor (Figure 2C). The TBA-P
was consistently within the 0-30% range (40 of the 44
assays; negative values counted as 0%) (Figure 2C).
There was a reduction in prevalence of greater than 75%
in only one feeding event. Like MRA39, in all 30 SMFAs,
TBA-I for the MRA38 antiserum ranged from 84 to
100% regardless of oocyst prevalence in the respective
negative controls (Figure 2B). However, in contrast to
MRA39, reductions in prevalence were more variable
with MRA38, and TBA-P above 75% was achieved in 13
of the 30 SMFAs (Figure 2D). There was a slight but in-
significant decline in TBA-P as oocysts numbers in the
respective negative controls increased (Figure 2D).
Transmission blocking activities of serum samples from
mice immunized with Pfs25
One hundred and eighty eight unknown serum samples
were tested, in duplicate, in 74 independently performed
SMFAs (Figure 3). The TBA-I (Figure 3A) and TBA-P
(Figure 3B) were reproducible between the duplicate as-
says for each sample when the percent inhibition was >75
and >80%, respectively. Below these values, the variability
between assays was higher. Out of the 188 sera tested, five
and nine serum samples enhanced oocyst infection intensity
and infection prevalence, respectively, compared to the
corresponding negative control (pre-immune) serum. Of
the 188 sera tested, 31 sera demonstrated 100% TBA-I
and 100% TBA-P, and 94 and 70 serum samples had
TBA-I or TBA-P in the 90-99% range, respectively
(Table 2).ocysts Infection prevalence (percent of mosquitoes
with oocysts)
dy TBA-I Negative control Pfs25 antibody TBA-P
81.6 ± 12.9 93.8 ± 7.2 81.9 ± 16.5 12.9 ± 16.6
77.7, 85.4 91.7, 96.0 77.0, 86.8 8.0, 17.8
36.5, 98.9 71.4, 100.0 8.3, 100.0 −8.7, 89.6
97.0 ± 3.9 94.6 ± 4.4 34.6 ± 27.1 63.5 ± 28.6
95.6, 98.4 92.9, 96.3 24.9, 44.3 53.3, 73.7
87.4, 100.0 84.2, 100.0 0, 79.2 10.0, 100.0
94.2 ± 6.3
92.7, 95.6
71.4, 100.0
d to show the infection intensity and infection prevalence in mosquitoes
ansmission blocking activities measured as effects on intensity (TBA-I) and
ntrol mosquitoes and one cage of positive control mosquitoes. For infection
ic mean intensities from each cage of negative or positive control mosquitoes
ta are the arithmetic means ± SD of the percent of mosquitoes infected in each
Figure 2 Effect of blood meal quality on transmission blocking effect of two anti-Pfs25 monoclonal antibodies. The relationship between
infection intensity (geometric mean number of oocysts) in control mosquitoes and the infection intensity (A, B) and infection prevalence (proportion
of mosquitoes with oocysts) (C, D) is plotted for mosquitoes fed anti-Pfs25 antibodies, MRA39 (A, C) and MRA38 (B, D) in the infectious blood meals.
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exposure to antibodies against Pfs25, and sample size
In order to demonstrate consistency of the SMFA
regardless of infection intensity and prevalence in negative
controls, the relationship between the log of the geometric
mean oocyst intensity and the prevalence was examined
separately for the two positive control antibodies (Figure 4A,
B), their respective negative controls (Figure 4C, D) and
for the test serum samples (Figure 4E). The data were
first fitted using several functional forms of the over-
dispersion parameter (κ) and the best fitting model,
based on the lowest value for Akaike’s information
criterion, was the hyperbolic model (Table 3). This was
used to fit all data from different treatments and
sample sizes.
Data from control mosquitoes and those exposed to
Pfs25 antibodies fitted onto near identical curves (pa-
rameters for the hyperbolic model in each figure are
given in Table 4) with negative controls clustered at the
upper limit of the curve (Figure 4C, D) and those ex-
posed to antibodies to Pfs25 (Figure 4A, B, E) scattered
along the curve as intensity and prevalence were affected
by the antibody treatments. The analysis confirmed the
lesser effects of MRA39 (Figure 4B) versus MRA38
(Figure 4A) on prevalence and intensity of infection. In-
fection characteristics in mosquitoes fed MRA39 were
more similar to controls, clustering to the upper right of
the curve, whereas those fed MRA38 demonstrated aclear separation from controls and had consistently bet-
ter reductions in prevalence rates and intensities. This
pattern was mirrored in samples fed the experimental
sera (Figure 4E). Here, the samples were blinded so it is
possible that some samples were serum from placebo
controls. Nevertheless, the various test samples were
clearly distributed along the similar curves, demonstrat-
ing the robust nature of the SMFA and the persistence
of the log-linear relationship. Surprisingly, there is little
difference between treatments at low intensities and
prevalence rates, but small differences appear at the
higher infection rates. For each treatment, the 95%
confidence bounds described by the model (shown as
shaded areas around each curve) indicate that the model
is an excellent fit to the data, with wider confidence
bounds seen only where data associated with any
treatment are sparse. For example, the wide 95% confidence
bounds at the high end of the curve in Figure 4A and B
are reflective of any data in these regions to allow model
validation. The tight 95% confidence intervals for the
fitted curves to the pooled data treatments (shaded area
Figure 4F) reinforce the robust and reproducible nature of
the assay based on the relationship between intensity and
prevalence.
Evaluation of an SMFA to demonstrate its robustness
and reproducibility is dependent upon the distribution
of the data, which in turn govern the sample size
required for assessment of TBA. The effects of sample
Figure 3 Transmission blocking activity based on infection intensity of 188 unknown sera. Samples are arranged in rank order of TBA.
Each point indicates the arithmetic mean percent TBA of two independent assays and error bars represent the range of percent TBA. (A) TBA-I.
Five sera increased infection intensity and 125 sera demonstrated >90% TBA-I. There was higher variability in TBA-I between duplicate assays in
samples with <70% reduction in infection intensity. (B) TBA-P. Nine sera increased infection prevalence and 101 sera demonstrated >90% TBA-P.
High variability in TBA-P between duplicate assays was observed only in sera with <80% reduction in prevalence.
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were examined (Figure 5). Regardless of sample size
(<20 mosquitoes (Figure 5A), 21–25 mosquitoes
(Figure 5B) or >25 mosquitoes (Figure 5C)), the samples
fitted to the same log-linear distribution, although theTable 2 Frequency distribution of reductions in intensity
and prevalence of P. falciparum oocyst stage infections in
A. stephensi for 188 serum samples tested in SMFA
Range of TBA Number (%) of test sera with corresponding
reduction in oocyst infection
Intensity (geometric mean
oocysts/mosquito)
Prevalence (percent
mosquitoes with oocysts)
100% 31 (16.5%) 31 (16.5%)
90-99% 94 (50.0%) 70 (37.2%)
60-89% 38 (20.2%) 31 (16.5%)
30-59% 17 (9.0%) 16 (8.5%)
0-29% 3 (1.6%) 31 (16.5%)
<0% 5 (2.7%) 9 (4.8%)distribution in samples of <20 mosquitoes were more
scattered. However, it is clear that under the conditions
described, increasing the numbers of mosquitoes assessed
above 25 did not greatly increase the robustness and
reproducibility of the assay.
Discussion
Sexual erythrocytic and mosquito stage VIMTs are being
developed with the expectation that they will play an
important role in malaria elimination campaigns, and
ultimately in malaria eradication. Such vaccine development
has been carried out largely in research laboratories with
limited capacity for scaling up the SMFA and for repeated
throughput under highly controlled conditions, and often
do not or cannot establish and maintain the rigorous qual-
ity control measures required of clinical laboratories or
manufacturing facilities. By contrast, Sanaria routinely
manufactures PfSPZ that meet all regulatory standards
[9,17-25]. To do this Sanaria has established robust P.
falciparum culture conditions and gametocyte production,
Figure 4 Relationship between intensity and prevalence of P. falciparum oocysts in mosquitoes fed control monoclonal antibodies and
test sera. (A) MRA38 monoclonal antibody (B) MRA39 monoclonal antibody; (C, D) Negative control sera for (A) and (B) respectively; (E)
Unknown experimental sera; (F) All data pooled to show consistency of relationship between the infection characteristics in all experiments.
Shaded area is 95% confidence interval round the curve for the pooled data.
Table 3 Results of models fit to assess different functional
forms of K, the overdispersion parameter [16,31]
Model Functional form Log likelihood AIC
Linear k(M) = αM + ε - 3204.317 6412.633
Power k(M) = αMβ + ε - 3203.071 6412.142
Hyperbolic k Mð Þ ¼ αM1þγM þ ε - 3202.466 6410.931
Sigmoid k Mð Þ ¼ αMβ
1þγMβ þ ε - 3202.357 6412.714
While all models fit the data similarly, the hyperbolic model was chosen as the
final model based on its lowest Akaike’s information criterion (AIC).
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feeding methods that reproducibly yield highly infected A.
stephensi mosquitoes. In order to monitor P. falciparum
infections in mosquitoes Sanaria also routinely measures
oocyst infection intensity and prevalence, and these
assessments are performed and analysed by a team of
trained staff members. Previous studies have developed
medium to high throughput assays for mosquito and
sexual stages of malaria that can be assessed in vitro [26]
and a version of the SMFA that, after the feeding event,
utilizes a P. falciparum strain derived from NF54 that has
Table 4 Parameter estimates from best fitting (hyperbolic)
model
Treatment α γ ε
All data −57. 1 (−57.6, −52.1) 12. 6 (8.0, 35.8) 5.3 (2.3-7.9)
1. −0.10 (−60.6, 40.6) 1. 1 (−0.03, 44.6) 1.1 (−1.0, 12.0)
2. −5. 5 (−25.5, 1.4) 5.1 (−0.24, 9.5) 1.7 (0.1, 5)
3. −12.3 (−17.6, 0.6) −105.3 (−600.5, 622.2) 0.8 (0.4, 0.9)
4. −85.1 (−108.9, 0.4) 19.3 (−.02, 28.0) 5.4 (0.5, 7.4)
5. −1.8 (−15.9, 0.9) −248.1 (−344.4, 479.5) 0.8 (0.7, 1.0)
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Protein-Luciferase for semi-automated downstream pro-
cessing [27]. While such assays do provide higher through-
put alternatives to the downstream (i.e. oocyst detection)
elements of the SMFA, they are restricted to the genetically
modified strain for assessment of transmission blocking
effects. Consequently, the SMFA remains the gold standard
for determining the effects of drugs or vaccines on trans-
mission of multiple strains of P. falciparum from human
host to mosquito vector. By exploiting its Good Manufac-
turing Practice (GMP) and Good Laboratory Practice
(GLP) capabilities, Sanaria has developed an industrialized
SMFA capacity to screen and evaluate SSM-VIMT and
TB drug candidates that are in preclinical and clinical
development, and can assess hundreds of samples in a
relatively short period of time. This paper analyses the
data generated from blinded SMFAs on 188 serum sam-
ples, performed semi-continuously, to conduct SMFA at
an industrial scale with a high degree of reproducibility.
The efficacy of sexual erythrocytic and mosquito stage
VIMTs [28], drugs [29], and other targeted interventions
(e.g., [30]) are calculated based on percent reductions in
infection (oocyst) intensity, infection (oocyst) prevalence
or both. However, efficacy estimates from an assay system
operated infrequently at widely spaced time intervals are
subject to uncertainty from variables that impact each
individual SMFA. These variables include oocyst intensity
and prevalence in the control group, the number ofFigure 5 Effect of sample size on the relationship between intensity a
monoclonal antibodies and test sera. Experimental sera plus negative co
plotted against based on sample size of (A) ≤20 mosquitoes per sample (r
sample or (C) ≥25 mosquitoes per sample (range = 25–28 mosquitoes perexperiments, and the number of mosquitoes analysed
per experiment [31]. Moreover, it is inappropriate to
calculate TBA-I from arithmetic means, though this has
been used in previous studies [32,33], because oocyst in-
fection intensity follows a negative binomial distribution
at low intensities, but is closer to a Poisson distribution
at high intensities [16,34,35]. Therefore, oocyst intensity
should be presented as geometric mean if the data for
any of the samples in the analysis are skewed, and TBA-I
should be calculated based on geometric mean intensity
of infection. In the present study the geometric mean oo-
cyst intensities were therefore used to determine TBA-I
for all samples.
While TBA of a given test sample is expressed typic-
ally as the percent reduction in oocyst infection intensity
compared to a negative control [7,11,36], investigators
have also analysed effects of antibodies or drugs on in-
fection prevalence rates (TBA-P), measuring the propor-
tion of fed mosquitoes exhibiting one or more oocysts
[16,26,35] or any detectable sporozoites [37]. To provide
a more complete picture of the effects of different TB
treatments, both TBA-I and TBA-P oocyst infection data
derived from dissections of 14–28 mosquitoes per sam-
ple are reported. As has been reported in previous stud-
ies [31], TBA based on measurement of TBA-I is greater
than that based on measurement of TBA-P: 81.55% TBA-
I versus 12.89% TBA-P for anti-Pfs25 antiserum MRA39,
and 94.63% TBA-I versus 63.52% TBA-P for anti-Pfs25
antiserum MRA38. Within any given experiment, the con-
sistent proportional reduction after Pfs25 antibody treat-
ment compared to the respective controls indicates that
the infectivity of the cultures was correlated for each inde-
pendent experiment. Since the average number of oocysts
in the control was not correlated with the percent reduc-
tion (Figure 2), this means that the dilution used (1:54
final dilution) of the control antibody contained suffi-
cient activity to be able to quantify transmission reduc-
tion at even high control infection rates. Furthermore,
the narrowness of these confidence intervals supportsnd prevalence of P. falciparum oocysts in mosquitoes fed control
ntrol serum and positive controls (MRA38 and MRA39) where were
ange = 14–20 mosquitoes per sample), (B) 21–24 mosquitoes per
sample). Symbols match those in Figure 4.
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ship between effects on infection intensity and prevalence
is an important consideration in evaluating transmission-
blocking interventions when the ultimate goal is to reduce
prevalence rates to levels that can interrupt transmission
in the field, in other words reduce the basic reproductive
rate, R0, to a value less than 1 [38].
The dataset generated in this study is unique in terms of
scale and consistency of method, and species and strains
of parasite and vector. This consistency is reflected in the
typically high reproducibility between results of duplicate
feeding events (Figure 3) regardless of control infectivity
and TBA-I or TBA-P. Duplicate rather than the typical
triplicate assessments of a given sample were performed
to allow higher throughput of the SMFA and was based
on the high confidence in, and consistency of, the SMFA
at Sanaria. Figure 3 now provides a powerful decision tool
for future SMFAs at Sanaria. The occasional large differ-
ence between duplicate assays can be seen in the figure
and will allow Sanaria to perform additional feeds on test
samples where the difference between results is consid-
ered to be unacceptably high.
To conduct routine SMFAs requires the ability to con-
tinuously generate adequate numbers of highly infected
mosquitoes. Sanaria has established a facility with fully
trained staff executing procedures that allow continuous
production of A. stephensi mosquitoes sustaining high P.
falciparum oocyst infection prevalence rates and inten-
sities. A. stephensi strain SDA500 mosquitoes and P. falcip-
arum strain NF54 gametocytes are produced continuously
and used to generate infected mosquitoes according to
standard operating procedures described in a Biologics
Master Files submitted to the US FDA. In 74 indepen-
dently performed SMFAs the geometric mean oocyst
infection intensity was 46.1 oocysts/mosquito and mean
infection prevalence of 94.2% for negative controls (Table 1).
Consistent infections are achieved through optimized and
rigorously controlled mosquito colony maintenance proce-
dures and gametocyte culture protocols that include
quality control monitoring of stage V gametocytaemia,
microgametocyte:macrogametocyte ratio and exflagella-
tion activity.
Variable TBA outcomes can be problematic in SMFA.
To address this, it is necessary to analyse a sufficient num-
ber of mosquitoes per treatment within a single SMFA to
derive reproducible measurements of TBA. Examination
of positive controls from 74 independent SMFAs using
two different anti-Pfs25 antisera [39] demonstrated that
feeding 30–35 mosquitoes and analysing a target 25 (actual
range 14–28) of these mosquitoes for oocyst infection
levels was sufficient to reliably measure TBA outcomes
(Table 3, Figure 2A, B). Further, it is clear that even sample
sizes below 20 mosquitoes can be sufficient to analyse the
results under the highly controlled SMFA conditionsdescribed here. Using both prevalence and intensity in a
fitted model provides the optimum use of all the available
data rather than restricting analysis to a single parameter.
It demonstrates the high consistency of the Sanaria’s SMFA
and resulting mosquito infections, and enables pooling of
subsets of data to be interrogated. Regardless of sample
size, all data fitted to the robust intensity-prevalence
relationship generated in Figure 4F. These findings are in
contrast with those based on simulation models [33] and
the Plasmodium berghei rodent parasite model [16], which
suggested that using fewer than 50 mosquitoes per feed
provided unrealistic TBA values. The reasons for this
discrepancy are unclear, but likely reflect the greater repro-
ducibility of SMFAs performed semi-continuously under
good manufacturing (GxP)-like conditions with tightly
controlled parameters.
A further important consideration to ensure that mean-
ingful TBA assessments can be obtained from SMFA is to
establish positive control antibody titres appropriate for
the levels of oocyst intensity achieved in negative control
assays. This was addressed in the present study by plotting
TBA in positive controls against mean infection (oocyst)
intensity and mean infection (oocyst) prevalence in the
negative controls. At the antibody dilution used (1:54), the
percent reduction in oocyst numbers (infection intensity)
was similar for low and high numbers of oocysts in con-
trols (Figure 2A, B). However, particularly for antibody,
MRA38, there was an indication that as the oocyst preva-
lence increased in the controls, the percent reduction in
oocyst numbers in mosquitoes fed the MRA38 antibody
decreased (Figure 2D).
The P. falciparum SMFA is both time consuming and
labour intensive. It requires the coordinated availability
of Anopheles mosquitoes and infective gametocyte stage
parasites. It is an expensive assay to perform, and for
preclinical research and development is best carried out
in a facility in which highly infected mosquitoes can be
safely produced, maintained and manipulated. Neverthe-
less, it represents the best current assay for measuring
the TB potential of candidate antibodies, drugs or other
targeted interventions. The current study represents, as
far as can be ascertained, the first report of an industrial
scale application of the SMFA to a large number of TB
experimental samples conducted semi-continuously and
highly reproducibly over an extended time period.
Conclusions
By focusing upon consistency of P. falciparum gametocyte
production, A. stephensi mosquito production, infectious
blood meal characteristics and feeding, and subsequent
maintenance of infected mosquitoes consistent with good
manufacturing practices (GMP). Sanaria has not only
standardized the SMFA but progressed it to a medium-
throughput system in which the TBAs of many unknown
Li et al. Malaria Journal  (2015) 14:150 Page 10 of 11samples can be assessed. Additionally, by including both
intensity and prevalence in the same model-fitting ana-
lysis, maximum use of the data is made in a statistically
robust way that incorporates control data integrated into
every feeding event.
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